- Home
- SHPH vs TNFA Comparison
SHPH vs TNFA Comparison
Compare SHPH & TNFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHPH
- TNFA
- Stock Information
- Founded
- SHPH 2012
- TNFA 2014
- Country
- SHPH United States
- TNFA United States
- Employees
- SHPH N/A
- TNFA N/A
- Industry
- SHPH Biotechnology: Pharmaceutical Preparations
- TNFA
- Sector
- SHPH Health Care
- TNFA
- Exchange
- SHPH Nasdaq
- TNFA NYSE
- Market Cap
- SHPH 3.2M
- TNFA 3.2M
- IPO Year
- SHPH 2022
- TNFA N/A
- Fundamental
- Price
- SHPH $0.62
- TNFA $0.48
- Analyst Decision
- SHPH
- TNFA
- Analyst Count
- SHPH 0
- TNFA 0
- Target Price
- SHPH N/A
- TNFA N/A
- AVG Volume (30 Days)
- SHPH 47.0K
- TNFA 852.2K
- Earning Date
- SHPH 03-20-2025
- TNFA 03-31-2025
- Dividend Yield
- SHPH N/A
- TNFA N/A
- EPS Growth
- SHPH N/A
- TNFA N/A
- EPS
- SHPH N/A
- TNFA N/A
- Revenue
- SHPH N/A
- TNFA N/A
- Revenue This Year
- SHPH N/A
- TNFA N/A
- Revenue Next Year
- SHPH N/A
- TNFA N/A
- P/E Ratio
- SHPH N/A
- TNFA N/A
- Revenue Growth
- SHPH N/A
- TNFA N/A
- 52 Week Low
- SHPH $0.58
- TNFA $0.45
- 52 Week High
- SHPH $4.71
- TNFA $3.60
- Technical
- Relative Strength Index (RSI)
- SHPH 36.32
- TNFA 26.35
- Support Level
- SHPH $0.66
- TNFA $0.45
- Resistance Level
- SHPH $0.79
- TNFA $0.66
- Average True Range (ATR)
- SHPH 0.06
- TNFA 0.09
- MACD
- SHPH -0.01
- TNFA -0.00
- Stochastic Oscillator
- SHPH 11.28
- TNFA 7.07
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.